Skip to main content
An official website of the United States government
Program Official
Principal Investigator
Shahzad Siddique
Awardee Organization

Commonspirit Health Research Institute
United States

Fiscal Year
2025
Activity Code
UG1
Early Stage Investigator Grants (ESI)
Not Applicable
Project End Date

CIRI Oncology Research Alliance

The CommonSpirit Health Research Institute (CSHRI) Oncology Research Alliance (CORA) seeks to continue to support and expand a community-based cancer research network, made up of community hospitals and cancer centers and incorporate best practices in enrolling patients to National Cancer Institute (NCI)sponsored cancer control, prevention, and care delivery clinical trials and other human subjects’ studies. The specific aims are: to increase enrollment in cancer control, prevention and care delivery clinical trials by providing access to a wide portfolio of high quality research studies that meet the needs of CORA’s various populations, annually accruing 10% of new cancer cases within the populations served by the network; and identify, design and implement Cancer Care Delivery Research (CCDR) that leads to improved models of care and translates to high-quality, value-based services throughout the oncology continuum. Applying CSHRI’s innovative, centralized and standardized organizational research model encompassing a network of geographically diverse community cancer programs, CSHRI will continue to provide the necessary resources for amplifying clinical trials across the country. CORA’s geographic reach and involvement with multiple distinct primary and sub-affiliates allow it to offer a wide portfolio of trials to large, established programs as well as small, rural sites and new regions that historically have had limited access to cancer clinical trials. Applying best practices from CORA to all current and new primary and sub-affiliates along with increased physician engagement will increase the number of patients screened and enrolled in clinical trials. Leveraging CommonSpirit Health’s (CSH) unique, well-positioned standard oncology electronic health records (EHRs), enterprise data warehouse, and analytics capabilities will continue to give CORA the depth of data and access to information needed to expand CCDR. CSH’s EHRs at CORA sites yield accessible data across the network that feeds into the data warehouse. CSH’s single network tumor registry database and EHR make CORA responsive to requests for data around patterns of care. Lastly, the advanced patient navigation, survivorship, and multidisciplinary conferences and disease site specific tumor boards already in place at all primary and sub-affiliate sites will support this research. Expanding to additional health systems and sites, and adding new investigators as opportunities arise will increase the number of patients that CORA can screen for enrollment in cancer clinical trials. CORA primary and sub-affiliates’ community outreach coordinators’ and navigators’ integrated efforts will be utilized to improve cancer control and prevention, detection, care delivery, and treatment for these populations. Continued growth of CORA’s community partner networks, translation support and nurse navigation training at all primary and sub-affiliate sites will help eliminate barriers to care.

Publications

  • Shadman M, Li H, Rimsza L, Leonard JP, Kaminski MS, Braziel RM, Spier CM, Gopal AK, Maloney DG, Cheson BD, Dakhil S, LeBlanc M, Smith SM, Fisher RI, Friedberg JW, Press OW. Continued Excellent Outcomes in Previously Untreated Patients With Follicular Lymphoma After Treatment With CHOP Plus Rituximab or CHOP Plus 131I-Tositumomab: Long-Term Follow-Up of Phase III Randomized Study SWOG-S0016. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018 Mar 1;36(7):697-703. Epub 2018 Jan 22. PMID: 29356608
  • Atkins MB, Lee SJ, Chmielowski B, Tarhini AA, Cohen GI, Truong TG, Moon HH, Davar D, O'Rourke M, Stephenson JJ, Curti BD, Urba WJ, Brell JM, Funchain P, Kendra KL, Ikeguchi AP, Jaslowski A, Bane CL, Taylor MA, Bajaj M, Conry RM, Ellis RJ, Logan TF, Laudi N, Sosman JA, Crockett DG, Pecora AL, Okazaki IJ, Reganti S, Chandra S, Guild S, Chen HX, Streicher HZ, Wolchok JD, Ribas A, Kirkwood JM. Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2023 Jan 10;41(2):186-197. Epub 2022 Sep 27. PMID: 36166727
  • Chung V, McDonough S, Philip PA, Cardin D, Wang-Gillam A, Hui L, Tejani MA, Seery TE, Dy IA, Al Baghdadi T, Hendifar AE, Doyle LA, Lowy AM, Guthrie KA, Blanke CD, Hochster HS. Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy: SWOG S1115 Study Randomized Clinical Trial. JAMA oncology. 2017 Apr 1;3(4):516-522. PMID: 27978579
  • Herbst RS, Redman MW, Kim ES, Semrad TJ, Bazhenova L, Masters G, Oettel K, Guaglianone P, Reynolds C, Karnad A, Arnold SM, Varella-Garcia M, Moon J, Mack PC, Blanke CD, Hirsch FR, Kelly K, Gandara DR. Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study. The Lancet. Oncology. 2018 Jan;19(1):101-114. Epub 2017 Nov 20. PMID: 29169877
  • Bradbury AR, Lee JW, Gaieski JB, Li S, Gareen IF, Flaherty KT, Herman BA, Domchek SM, DeMichele AM, Maxwell KN, Onitilo AA, Virani S, Park S, Faller BA, Grant SC, Ramaekers RC, Behrens RJ, Nambudiri GS, Carlos RC, Wagner LI. A randomized study of genetic education versus usual care in tumor profiling for advanced cancer in the ECOG-ACRIN Cancer Research Group (EAQ152). Cancer. 2022 Apr 1;128(7):1381-1391. Epub 2021 Dec 10. PMID: 34890045